HUE071473T2 - MIV-818/lenvatinib kombinációs terápia májrák kezelésére - Google Patents

MIV-818/lenvatinib kombinációs terápia májrák kezelésére

Info

Publication number
HUE071473T2
HUE071473T2 HUE21787576A HUE21787576A HUE071473T2 HU E071473 T2 HUE071473 T2 HU E071473T2 HU E21787576 A HUE21787576 A HU E21787576A HU E21787576 A HUE21787576 A HU E21787576A HU E071473 T2 HUE071473 T2 HU E071473T2
Authority
HU
Hungary
Prior art keywords
lenvatinib
miv
combination therapy
liver cancer
liver
Prior art date
Application number
HUE21787576A
Other languages
English (en)
Hungarian (hu)
Inventor
Fredrik Oeberg
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of HUE071473T2 publication Critical patent/HUE071473T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE21787576A 2020-04-15 2021-04-14 MIV-818/lenvatinib kombinációs terápia májrák kezelésére HUE071473T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE2050430 2020-04-15

Publications (1)

Publication Number Publication Date
HUE071473T2 true HUE071473T2 (hu) 2025-09-28

Family

ID=78084457

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21787576A HUE071473T2 (hu) 2020-04-15 2021-04-14 MIV-818/lenvatinib kombinációs terápia májrák kezelésére

Country Status (13)

Country Link
US (1) US20240024342A1 (https=)
EP (1) EP4135849B1 (https=)
JP (1) JP7709456B2 (https=)
KR (1) KR20230003522A (https=)
CN (1) CN115485029A (https=)
AU (1) AU2021255043B9 (https=)
CA (1) CA3174940A1 (https=)
ES (1) ES3027841T3 (https=)
HR (1) HRP20250669T1 (https=)
HU (1) HUE071473T2 (https=)
PL (1) PL4135849T3 (https=)
TW (1) TW202200140A (https=)
WO (1) WO2021211039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
TW202444368A (zh) * 2023-03-30 2024-11-16 瑞典商米迪維艾克提伯拉公司 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ729118A (en) * 2014-08-25 2022-02-25 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
CA3014769C (en) * 2016-03-02 2024-01-09 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
RU2019134940A (ru) * 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
US11098002B2 (en) * 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease

Also Published As

Publication number Publication date
HRP20250669T1 (hr) 2025-08-01
EP4135849A1 (en) 2023-02-22
JP2023522325A (ja) 2023-05-30
US20240024342A1 (en) 2024-01-25
EP4135849B1 (en) 2025-03-19
EP4135849A4 (en) 2024-04-17
WO2021211039A1 (en) 2021-10-21
ES3027841T3 (en) 2025-06-17
AU2021255043B2 (en) 2025-06-05
KR20230003522A (ko) 2023-01-06
PL4135849T3 (pl) 2025-07-14
CN115485029A (zh) 2022-12-16
JP7709456B2 (ja) 2025-07-16
AU2021255043A1 (en) 2022-11-03
EP4135849C0 (en) 2025-03-19
AU2021255043B9 (en) 2025-07-10
CA3174940A1 (en) 2021-10-21
TW202200140A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
ZA202106392B (en) Therapeutic rna for prostate cancer
IL282093A (en) Combination therapy for cancer
IL307964A (en) Combined treatment for cancer
GB201905780D0 (en) Cancer therapy
PT4225297T (pt) Terapia de combinação para o tratamento de cancro
PL4190173T3 (pl) Metaboliczna terapia przeciwnowotworowa
SG11202106295WA (en) Compositions and methods for cancer therapy
ZA202310076B (en) Combination therapies for treating cancer
IL300171A (en) Combined treatment against cancer
IL304436A (en) Cancer treatment
PL4135849T3 (pl) Terapia skojarzona miv-818/lenwatynib na raka wątroby
GB202301902D0 (en) Combination therapy for cancer
GB202208347D0 (en) Targets for cancer therapy
GB202218395D0 (en) Cancer therapy
IL321575A (en) Combination therapy for lung cancer
EP4251133C0 (en) COMBINED CANCER THERAPY
GB202001963D0 (en) Cancer therapy
SG11202109025XA (en) Combinations of iadademstat for cancer therapy
EP3981473A4 (en) Therapeutic agent for cancer
GB202116680D0 (en) Combination therapy for cancer
GB202103673D0 (en) Combination therapy for cancer
GB202208893D0 (en) Combination therapy for cancer
HK40117032A (en) Combination therapy for cancer
GB202318158D0 (en) Cancer therapy
HK40096988A (en) Combination therapy for cancer